{"id":"W3176956457","doi":"10.1158/1078-0432.ccr-21-0793","title":"Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Ipilimumab; Pembrolizumab; Medicine; Cohort; Regimen; Internal medicine; Adverse effect; Dosing; Melanoma; Incidence (geometry); Gastroenterology; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002811536,0.001885689,0.001620044,0.0006629744,0.0005717139,0.001161188,0.001081976,0.001613408,0.006252561],"category_scores_gemma":[0.001218504,0.0009020405,0.001147694,0.0004758892,0.001159606,0.001175425,0.0004089563,0.003795523,0.001431388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001372786,"about_ca_system_score_gemma":0.001741321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007264754,"about_ca_topic_score_gemma":0.001668223,"domain_scores_codex":[0.9992141,0.0003504453,0.00005559734,0.000174891,0.00008379359,0.0001212101],"domain_scores_gemma":[0.9987839,0.0001631892,0.0003064985,0.0001392582,0.00008457316,0.0005226419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8752188,0.07870995,0.003102319,0.0005572651,0.0006718336,0.0000898157,0.0001195643,0.0008512583,0.01489625,0.000198881,0.002375943,0.02320816],"study_design_scores_gemma":[0.7176138,0.2738353,0.004263597,0.00002398157,0.0003263134,0.00008349421,0.00002426853,0.0004455471,0.001933504,0.0001071194,0.001320953,0.00002217268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989781,0.00124459,0.0004314087,0.000317935,0.0001597351,0.00498923,0.001578307,0.00006855273,0.001429061],"genre_scores_gemma":[0.9845077,0.001215172,0.001829068,0.0008055891,0.000287913,0.005747162,0.002006596,0.00003382651,0.003567044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006252561,"threshold_uncertainty_score":0.02091688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1385145977082808,"score_gpt":0.5370049475480762,"score_spread":0.3984903498397953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}